ARX201 is a long-acting recombinant human growth hormone drug candidate currently developed by Ambrx and Merck Serono for the treatment of growth hormone deficiencies. ARX201 was generated through a lead optimization process using Ambrx's ReCODE(TM) technology, which effectively enables protein medicinal chemistry. Through this approach, Ambrx was able to generate site specific mono-pegylated hGH molecules that were optimized for potency and time of action. Ambrx believes that ARX201 may have improved pharmacological performance over existing growth hormone products, including the potential for less frequent dosing.
In pre-clinical studies, ARX201 met or exceeded key end points in assays that are believed to be predictive of human pharmacokinetics and biological response. In February 2007, a Phase I/II clinical trial of ARX201 was initiated to investigate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of this product candidate in adult patients with growth hormone deficiency following single-dose escalation and repeated dosing.
Ambrx Inc. is a clinical stage biopharmaceutical company with a broad
biologics platform that allows it to create best-in-class protein
therapeutics, including improved versions of native proteins and
therapeutic antibodies. Its most advanced product candidate, ARX201, is a
long-acting human growth hormone drug candidate partnered with Merck Serono
that has successfully completed initial clinical trials. The company has
further validated its biologics platform through substantial partnerships
with Eli Lilly and Company and Merck & Co. Ambrx is advancing a robust
portfolio of product opportunities spanning multiple therapeutic are
|SOURCE Ambrx Inc.|
Copyright©2008 PR Newswire.
All rights reserved